ADC Therapeutics (ADCT) Share-based Compensation (2023 - 2026)

ADC Therapeutics has disclosed Share-based Compensation across 4 years of filings, most recently posting $2.4 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.4 million, up 0.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (down 21.57% YoY), and the FY2025 annual result was $6.9 million, up 5.13% from the prior year.
• Share-based Compensation came in at $2.4 million for Q1 2026 at ADC Therapeutics, up from $673000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $8.1 million in Q1 2023 to a low of $158000.0 in Q1 2024.
• The 4-year median for Share-based Compensation is $2.0 million (2025), against an average of $2.3 million.
• Across the five-year window, Share-based Compensation plunged 98.04% in 2024 and soared 1432.28% in 2025, its largest moves.
• ADC Therapeutics' Share-based Compensation stood at $2.2 million in 2023, then slipped by 27.21% to $1.6 million in 2024, then tumbled by 58.35% to $673000.0 in 2025, then jumped by 262.85% to $2.4 million in 2026.
• The last three Share-based Compensation figures came in at $2.4 million (Q1 2026), $673000.0 (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.